Silver Elephant Announces Annual General Meeting Voting Results

Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - Silver Elephant Mining Corp. (TSX: ELEF) (OTC Pink: SILEF) (FSE: 1P2N) ("Silver Elephant" or the "Company") is pleased to announce that all resolutions put forward at the Annual General Meeting (the "Meeting") of the Company's shareholders held May 10, 2024, as described in the Company's information circular dated March 27, 2024 (the "Circular"), were approved. A summary of the results are set out below:

• Number of Directions: set the number of directors at four (4).

• Election of Directors: the nominees listed in the Circular the Meeting were all elected as Directors until the next annual general meeting of the Shareholders. Detailed results of the vote are set out below:

• Approved the appointment of Mao & Ying LLP, Chartered Professional Accountants as the auditors of the Company and authorizing the directors to fix the remuneration to be paid to Mao & Ying LLP, Chartered Professional Accountants.

For more information on the voting results, please see the Report of Voting Results which is available at www.sedar.com.

About Silver Elephant Mining Corp.

Silver Elephant is a silver mining company, with its flagship Pulacayo-Paca silver project in production since October 2023 in Bolivia.

Further information on Silver Elephant can be found at www.silverelef.com.

SILVER ELEPHANT MINING CORP.
ON BEHALF OF THE BOARD

"John Lee"
Executive Chairman

For more information about Silver Elephant, please contact Investor Relations:
+1.604.569.3661 ext. 101
[email protected]
www.silverelef.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/209204

You May Also Be Interested In

• Tersis Technologies and Flux Core Sign MOU to Advance Decentralized Data Centers and Sustainable AI Compute
• Kingsport HVAC Expert Kyle Rodrigues Shares Simple Solutions for Heat Pump Heating Problems
• Drug Farm Presents Positive Ophthalmologic and Systemic Findings from International Phase 1b Study of First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at APVRS 2026